Kato Motohiro, Koh Katsuyoshi, Oshima Koichi, Oguma Eiji, Uchida Hiroo, Kishimoto Hiroshi, Kikuchi Akira, Hanada Ryoji
Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
Pediatr Int. 2013 Apr;55(2):245-8. doi: 10.1111/j.1442-200X.2012.03663.x.
The prognosis for metastatic malignant rhabdoid tumor (MRT) is poor, and metastatic (stage IV) MRT was resistant to conventional treatment, with less than 20% of cure rate. Moreover, there have been no reports of patients who have survived relapsed stage IV MRT. Here we report a long-term survivor of relapsed MRT with lung metastasis at diagnosis. He was diagnosed as MRT of the kidney at 5-month-old. After resection of the renal tumor, he was treated with ICE (ifosfamide, carboplatin, and etoposide), total abdominal irradiation 10.8 Gy and high-dose chemotherapy using thiotepa and melphalan. Six months after initial treatment, a relapse in the lung was detected, and he received chemotherapy including doxorubicin/pirarubicin for 78 weeks. He is alive at five years of follow up, without any evidence of disease. Our report suggests the important role of anthracycline in treatment of MRT.
